Novo, Partners Healthcare and Sham all contributed to a $74.6m round for Alizé Pharma 3, which is exploiting research from three US institutions.
Alizé Pharma 3, a France-based biopharmaceutical startup based on research at University of North Carolina (UNC) at Chapel Hill, University of Maine and Harvard University, secured €67m ($74.6m) on Tuesday in a series A round led by investment firm LSP.
Novo Ventures, Partners Innovation and Sham Innovation Santé, respective investment vehicles for pharmaceutical firm Novo, healthcare provider Partners Healthcare and insurer Sham, took part in the round.
Management consulting firm TAB and Crédit Agricole Creation, an investment vehicle for banking cooperative Crédit Agricole, as well as investment bank Bpifrance’s Innobio 2 fund, Kurma Partners, Orbimed and Pontifax also participated.
Alizé Pharma 3 is developing drugs that are intended to treat metabolic diseases and diseases of the endocrine system, the hormone-based messenger system that includes the thyroid and adrenal glands. It is the third entity to carry the Alizé Pharma name.
The original Alizé Pharma was acquired…
